3Rs for innovating novel antibiotics: Sharing resources, risks, and rewards

BMJ (Online)

Volumn 344, Issue 7852, 2012, Pages

  So, Anthony D ^a   Ruiz Esparza, Quentin ^a   Gupta, Neha ^a   Cars, Otto ^b  

^a DUKE UNIVERSITY   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIMALARIAL ACTIVITY; BACTERIAL GENOME; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FUNDING; GRAM NEGATIVE BACTERIUM; HUMAN; MEDICAL SOCIETY; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; REWARD; RISK;

ANTI-BACTERIAL AGENTS; COOPERATIVE BEHAVIOR; DRUG INDUSTRY; HUMANS; RESEARCH; RISK;

EID: 84859720143     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e1782     Document Type: Review

References (34)

1. Spellberg B, Powers J, Brass E, Miller L, Edwards J. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004;38:1279-86. (Pubitemid 38608571)
2. Aronsson B, Boscan IS, Cars O, Giamarellou H, Gyssens IC, Lutsar I, et al. The bacterial challenge: time to react. European Centre for Disease Prevention and Control and European Medicines Agency joint report. 2009 www.ema.europa.eu/pdfs/human/antimicrobial-resistance/EMEA-576176-2009.pdf
3. Hamad B. The antibiotics market. Nature Rev Drug Discovery 2006;9:675-6.
4. Projan SJ. Why is big pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003;6:427-30. (Pubitemid 37345405)
5. Mossialos E, Morel C, Edwards S, Berenson J, Gemmill-Toyama M, Brogan D. Policies and incentives to promote innovation in antibiotic research. Final report 2010. www.euro.who.int/--data/assets/pdf-file/0011/120143/E94241.
6. Kesselheim A, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff 2010;29:1689.
7. Payne D, Gwynn M, Holmes D, Pompliano D. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev Drug Discovery 2007;6:29-40. (Pubitemid 46020284)
8. Schmid M. Seeing is believing: the impact of structural genomics on antimicrobial drug discovery. Nature 2004;2:239.
9. ReAct. Collaboration for innovation - the urgent need for new antibiotics. ReAct policy seminar, 23 May 2011, Brussels, Belgium. www.reactgroup.org/uploads/news/Collaboration-for-Innovation-The-Urgent-Need- for-New-Antibiotics-ReAct-Policy-Seminar-Brussels-May-23-2011.pdf.
10. Bleicher K, Bohm H, Muller K, Alanine A. Hit and lead generation: beyond high-throughput screening. Nature Rev Drug Discovery 2003;2:369.
11. Fischer A, Borensztein P, Roussel C. The European rare diseases therapeutic initiative. PLoS Med 2005;2:e243.
12. Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, Ridley R. Advancing drug innovation for neglected diseases - criteria for lead progression. PLoS Negl Trop Dis 2009;8:e440.
13. Rai AK, Reichman JH, Uhlir PF, Crossman C. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery. Yale J Health Law, Policy, Ethics 2008;8:53-89.
14. Coalition Against Major Diseases. www.c-path.org/CAMD.cfm
15. Austin C, Brady L, Insel T, Collins F. NIH molecular libraries initiative. Science 2004;306:1138.
16. Collins F. Reengineering translational science: the time is right. Science Transl Med 2011;3:90:90cm17. www.nih.gov/about/director/articles/ translational-science-07062011.pdf.
17. Goss C, Mayer-Hamblett N. The Cystic Fibrosis Foundation therapeutics development network: a national effort by the Cystic Fibrosis Foundation to build a clinical trials network. Children's Health Care 2008;37:5-20. (Pubitemid 351451040)
18. Ghosh S. How the young brigade mapped the TB genome. The Hindu 2010. http://beta. thehindu.com/sci-tech/article397395.ece.
19. Nwaka S, Ilunga T, Da Silva J, Verde E, Hackley D, Vre R, et al. Developing ANDI: a novel approach to health product R&D in Africa. PLoS Medicine 2010;7:e1000293.
20. GlaxoSmithKline. GlaxoSmithKline awarded US Department of Defense contract to pursue novel antibacterial research program. 2007. http://us.gsk.com/html/media-news/pressreleases/2007/2007-09-18-GSK1146.htm.
21. Fikes B. Trius receives $29.5 million contract to find microbe antibiotics. North County Times 2010 Sep 20. www.nctimes.com/business/article- bb6141ed-f20b-5016-b00e-96a2bacab749.html.
22. http:///US Department of Health & Human Services. BARDA funds drug development for biothreats, antibiotic resistance. Press release, 30 August 2010. www.hhs.gov/news/press/2010pres/08/20100830a.html.
23. Wellcome Trust. Therapeutics. 2010. www.wellcome.ac.uk/Funding/ Technology-transfer/Funded-projects/therapeutics/index.htm.
24. Innovative Medicines Initiative. NewDrugs4BadBugs (ND4BB). www.imi.europa.eu/content/future-topics.
25. DiMasi J, Grabowski H, Vernon J. R&D costs and returns by therapeutic category. Drug Info J 2004;38:211-23.
26. BCC Research. Infectious disease treatments: global markets. 2010. www.bccresearch.com/report/PHM061A.html.
27. BCC Research. Therapeutic drugs for central nervous system (CNS) disorders: technologies and global markets. 2010. www.bccresearch.com/report/ PHM068A.html.
28. BCC Research. Cardiovascular therapeutic drugs: technologies and global markets. 2010. www.bccresearch.com/report/cardiovascular-therapeutic-drugs- phm024b.html.
29. Hamad B. The antibiotics market. Nature Rev Drug Discovery 2010;9:675-6.
30. Laxminarayan R. Antibiotic resistance: can economic incentives play a role? 2001. www.rff.org/RFF/Documents/RFF-Resources-143-antibiotic.pdf.
31. Kesselheim A, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff 2010;29:1689.
32. Govtrack.us. Text of H.R. 2182: Generating Antibiotic Incentives Now Act of 2011. www.govtrack.us/congress/billtext.xpd?bill=h112-2182.
33. Bergström R. The role of the pharmaceutical industry in meeting the public health threat of antibacterial resistance. Drug Resist Updates 2010;14:77-8.
34. ASAQ: Hope for Malaria. New, once-a-day fixed-dose combination against malaria now available. Press release, 1 March 2007. www.actwithasaq.org/en/ press-2.htm.